The restructuring events database contains factsheets with data on large-scale restructuring events reported in the principal national media and company websites in each EU Member State. This database was created in 2002.
Manufacturing (20 - 21) Manufacture of chemicals and pharmaceuticals 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations 21 - Manufacture of basic pharmaceutical products and pharmaceutical preparations
650 jobs Number of planned job losses
Announcement Date
21 February 2013
Employment effect (start)
21 February 2013
Foreseen end date
Description
Pharmaceutical company Abbott is currently in the process of making 650 of its staff in Ireland and the US redundant. The company, which produces pharmaceuticals, medical and nutritional products, says that these job reduction measures form part of a previously communicated adjustment strategy set out to increase its efficiency.
According to reports, the company has issued redundancy notices at its Temecula plant in California, US, which specializes in vascular devices, affecting 450 of its staff. The job cuts were primarily located in the company’s manufacturing and manufacturing support divisions, affecting full-time employees only. While the Temecula plant continues to employ around 2,000 staff, the plant has witnessed a loss of 1,000 positions since January 2012.
At the same time, the company also intends to eliminate 200 positions in Ireland. The job cuts will be affected at the company’s Clonmel plant, which also specializes in vascular devices and currently employs around 1,400 staff. According to Abbott, these job reduction measures have become necessary due to a downturn in demand for the company’s older products.
According to reports, the company wants to focus on voluntary redundancies and also plans to not renew temporary contracts. Moreover, Abbott remains committed to assist those affected by redundancies and in Ireland a 30-day consultation period with employees has been initiated.
The global healthcare company currently employs around 70,000 employees across 150 countries. American based Abbott has been continuously reducing its staff over the past 3 years (see here).
Sources
21 February 2013: The Press Enterprise
21 February 2013: Belfast Telegraph
21 February 2013: FierceMedicalDevices
21 February 2013: Murrieta Patch
Citation
Eurofound (2013), Abbott, Internal restructuring in World, factsheet number 74968, European Restructuring Monitor. Dublin, https://apps.eurofound.europa.eu/restructuring-events/detail/74968.
Eurofound’s ERM restructuring legislation database offers an overview of key restructuring-related regulations in the EU Member States and Norway. Its content is continuously updated to reflect any changes made by national legislators in response to, for instance, policy shifts, legal...
Can Europe still achieve its ambitions for battery manufacturing? To answer this, the article looks at data from Eurofound’s European Restructuring Monitor and explores what recent large-scale restructuring events reveal about the state of play in the EU battery sector.
This working paper offers a comprehensive methodological overview of the European Restructuring Monitor (ERM) databases. Even though the methodology has not changed over time, new categories have been added, and the way it has been used by researchers and policymakers...
This Eurofound research paper explores key trends in restructuring in recent years, highlighting the companies that announced the largest job losses and job gains in the EU. It builds on an analysis of company announcements recorded in Eurofound’s European Restructuring...
In 2023, thousands of workers in big tech lost their jobs. Meta, Amazon, Google, Apple, Microsoft and Salesforce had been considered to offer good and secure jobs up to this point. Giants of the information and communication technology (ICT) sector,...
In 2024, the automotive sector in the EU came to the fore in public and policy discussions. The focus was on the slowdown in electric vehicle (EV) sales, rising global competition, belated investments in new technologies, and the potential closure...